Document Detail


Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
MedLine Citation:
PMID:  16857689     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Although linezolid has good in vitro activity against Mycobacterium tuberculosis, its long-term use in the treatment of multidrug-resistant tuberculosis (MDR-TB) may be limited by its cost and serious adverse reactions. We therefore evaluated the efficacy and tolerability of a reduced dose of linezolid, in combination with other anti-TB drugs, in patients with intractable or extensive MDR-TB. METHODS: MDR-TB patients unresponsive to at least three cycles of treatment were treated with daily-half doses of linezolid (600 mg once per day) plus at least four companion drugs. RESULTS: As of March 2006, eight patients, all HIV-negative, had been treated with linezolid for 3-18 months. Cultures became negative in all patients in an average of 82 days. Four patients developed peripheral neuropathy, two developed optic neuropathy and one developed anaemia. Although optic neuropathy resolved after cessation of linezolid therapy, peripheral neuropathy continued. One patient completed 18 months of linezolid therapy. Two patients, who have taken linezolid for 15-17 months, are still on treatment and remain in culture conversion. Three patients stopped linezolid after 7-9 months, two because of side effects and one for economic reasons, but remain on treatment with other second-line drugs with culture conversion. Two patients died from severe respiratory failure, but both previously had shown culture conversion. CONCLUSIONS: Although daily-half doses of linezolid were effective in patients with intractable or extensive MDR-TB, this dosage regimen did not reduce long-term use-related side effects, such as peripheral and optic neuropathy.
Authors:
I-Nae Park; Sang-Bum Hong; Yeon-Mok Oh; Mi-Na Kim; Chae-Man Lim; Sang Do Lee; Younsuck Koh; Woo Sung Kim; Dong Soon Kim; Won Dong Kim; Tae Sun Shim
Related Documents :
16604249 - Risk factors for candidemia-related mortality at a medical center in central taiwan.
6090539 - Infections caused by herpes simplex virus in the immunocompromised host: natural histor...
16898369 - Causes of death during tuberculosis treatment in tomsk oblast, russia.
8804799 - Fluconazole versus amphotericin b in the treatment of esophageal candidiasis in cancer ...
21054179 - Efficacy and safety of posaconazole for chronic pulmonary aspergillosis.
1322949 - Treatment of dermatophytosis with new systemic antifungal agent, itraconazole.
15022019 - High-energy laser therapy of barrett's esophagus: preliminary results.
17171049 - Predictive value of postoperative electrophysiologic testing of the facial nerve after ...
18495699 - Is it worth performing surgical ventricular restoration in patients with ischemic cardi...
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2006-07-19
Journal Detail:
Title:  The Journal of antimicrobial chemotherapy     Volume:  58     ISSN:  0305-7453     ISO Abbreviation:  J. Antimicrob. Chemother.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-09     Completed Date:  2006-11-06     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7513617     Medline TA:  J Antimicrob Chemother     Country:  England    
Other Details:
Languages:  eng     Pagination:  701-4     Citation Subset:  IM    
Affiliation:
Division of Pulmonary & Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, 388-1 Pungnap-dong, Songpa-gu, Seoul, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acetamides / administration & dosage,  adverse effects,  therapeutic use*
Adolescent
Adult
Antitubercular Agents / administration & dosage,  adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Resistance, Multiple, Bacterial* / drug effects
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Mycobacterium tuberculosis / drug effects*,  isolation & purification
Oxazolidinones / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Tuberculosis, Pulmonary / drug therapy*,  microbiology
Chemical
Reg. No./Substance:
0/Acetamides; 0/Antitubercular Agents; 0/Oxazolidinones; 165800-03-3/linezolid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxiflox...
Next Document:  Optimal sampling strategies for early pharmacodynamic measures in tuberculosis.